ReviewBiologics : targets & therapy2014
Therapeutic vaccines and cancer: focus on DPX-0907.
Review in Biologics : targets & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy.Frontiers in immunology · 2022Pooled it
- Bioresponsive engineered nanoparticles for immunomodulation.BMC medicine · 2025Review
- Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines.Nano research · 2025Article
- Engineering Nanoparticles to Modulate Extracellular Matrix and Immune Components of the Tumor Microenvironment in Cancer Immunotherapy.Biomaterials research · 2025Review
- Peptide-based vaccine for cancer therapies.Frontiers in immunology · 2023Review
- The progress of peptide vaccine clinical trials in gynecologic oncology.Human vaccines & immunotherapeutics · 2022Review
- Sustained Drug Release from Smart Nanoparticles in Cancer Therapy: A Comprehensive Review.Micromachines · 2022Review
- Nanomedicine-Based Delivery Strategies for Breast Cancer Treatment and Management.International journal of molecular sciences · 2022Review
- Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks.Pharmaceutics · 2021Review
- Article
- Nanotechnology synergized immunoengineering for cancer.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021Review
- Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.Advances in experimental medicine and biology · 2021Article
- Review
- Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease.Medicine · 2019Observational
- Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation.Drug discovery today · 2019Review
- Peptide-based materials for cancer immunotherapy.Theranostics · 2019Review
- Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.Theranostics · 2019Review
- Biomaterial-assisted targeted modulation of immune cells in cancer treatment.Nature materials · 2018Review
- A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.Drug discovery today · 2018Review
- Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.Journal of controlled release : official journal of the Controlled Release Society · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In an attempt to significantly enhance immunogenicity of peptide cancer vaccines, we developed a novel non-emulsion depot-forming vaccine platform called DepoVax™ (DPX). Human leukocyte antigen (HLA)-A2 restricted peptides naturally presented by cancer cells were used as antigens to create a therapeutic cancer vaccine, DPX-0907. In a phase I clinical study, the safety and immune-activating potential of DPX-0907 in advanced-stage breast, ovarian, and prostate cancer patients were examined, following encouraging results in HLA-A2 transgenic mice. The DPX-0907 vaccine was shown to be safe and well tolerated, with injection-site reactions being the most commonly reported adverse event. Vaccinated cancer patients exhibited a 61% immune response rate, with higher response rates in the breast and ovarian cancer patient cohorts. In keeping with the higher immune efficacy of this vaccine platform, antigen-specific responses were detected in 73% of immune responders after just one vaccination. In 83% of responders, peptide-specific T-cells were detected at two or more time points post-vaccination, with 64% of these patients showing evidence of immune persistence. Immune monitoring also demonstrated the generation of antigen-specific T-cell memory, with the ability to secrete multiple type 1 cytokines. The novel DPX formulation promotes multifunctional effector/memory responses to peptide-based tumor-associated antigens. The data support the capacity of DPX-0907 to elicit type-1 biased immune responses, warranting further clinical development of the vaccine. In this review, we discuss the rationale for developing DPX-based therapeutic cancer vaccine(s), with a focus on DPX-0907, aimed at inducing efficient anti-tumor immunity that may eventually be shown to prolong patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.